# Siga Technologies Inc: overview

SIGA · Nasdaq · CIK 1010086 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/siga.md) · [Financials](/companies/siga/financials.md) · [Filings](/companies/siga/filings.md) · [Insiders](/companies/siga/insiders.md)

Latest reported revenue: [$41.0m](/filings/0001437749-26-026314.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-026314).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.0](/filings/0001437749-25-033636.md) | [81.5 d](/filings/0001437749-26-007557.md) | [7.0](/filings/0001437749-26-015646.md) | [81.1](/filings/0001437749-26-026314.md) | [2.6](/filings/0001437749-25-033636.md) | [3.8 d](/filings/0001437749-26-007557.md) | [6.2](/filings/0001437749-26-015646.md) | [41.0](/filings/0001437749-26-026314.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [5.4%](/filings/0001437749-25-033636.md) | [70.1% d](/filings/0001437749-26-007557.md) | [(32.0%)](/filings/0001437749-26-015646.md) | [56.3%](/filings/0001437749-26-026314.md) | [(390.2%)](/filings/0001437749-25-033636.md) | [(250.4%) d](/filings/0001437749-26-007557.md) | [(85.2%)](/filings/0001437749-26-015646.md) | [33.9%](/filings/0001437749-26-026314.md) |
| Net margin | % | [13.4%](/filings/0001437749-25-033636.md) | [56.2% d](/filings/0001437749-26-007557.md) | [(5.8%)](/filings/0001437749-26-015646.md) | [43.7%](/filings/0001437749-26-026314.md) | [(243.0%)](/filings/0001437749-25-033636.md) | [(143.1%) d](/filings/0001437749-26-007557.md) | [(55.3%)](/filings/0001437749-26-015646.md) | [30.4%](/filings/0001437749-26-026314.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001437749-25-033636.md) | not reported | [(0.01)](/filings/0001437749-26-015646.md) | [0.49](/filings/0001437749-26-026314.md) | [(0.09)](/filings/0001437749-25-033636.md) | not reported | [(0.05)](/filings/0001437749-26-015646.md) | [0.17](/filings/0001437749-26-026314.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [134](/filings/0001437749-24-007487.md) | [111](/filings/0001437749-25-007056.md) | [140](/filings/0001437749-26-007557.md) | [139](/filings/0001437749-26-007557.md) | [94.6](/filings/0001437749-26-007557.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [66.7%](/filings/0001437749-24-007487.md) | [38.5%](/filings/0001437749-25-007056.md) | [59.8%](/filings/0001437749-26-007557.md) | [50.4%](/filings/0001437749-26-007557.md) | [25.1%](/filings/0001437749-26-007557.md) |
| Net margin | % | [52.0%](/filings/0001437749-24-007487.md) | [30.6%](/filings/0001437749-25-007056.md) | [48.6%](/filings/0001437749-26-007557.md) | [42.7%](/filings/0001437749-26-007557.md) | [24.6%](/filings/0001437749-26-007557.md) |
| Diluted EPS | $ per share | [0.91](/filings/0001437749-24-007487.md) | [0.46](/filings/0001437749-25-007056.md) | [0.95](/filings/0001437749-26-007557.md) | [0.82](/filings/0001437749-26-007557.md) | [0.32](/filings/0001437749-26-007557.md) |
| Free cash flow | $m | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/siga/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.2m | 4,186,282 |  | Added +692,089 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $9.9m | 2,719,568 |  | Added +16,844 |
| [AltraVue Capital, LLC](/funds/1740837.md) | 2026-06-30 | $8.5m | 2,327,144 |  | Reduced −104,880 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.2m | 1,712,701 |  | Reduced −1,679 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $5.5m | 1,506,065 |  | Added +188,281 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $5.4m | 1,474,817 |  | Reduced −51,143 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $5.2m | 1,417,092 |  | Added +101,547 |
| [FIRST WILSHIRE SECURITIES MANAGEMENT INC](/funds/732847.md) | 2026-06-30 | $4.9m | 1,339,883 |  | Added +449,385 |
| [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $4.5m | 1,245,992 |  | Added +26,315 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.1m | 1,133,989 |  | Added +122,051 |

## Recent filings

[All 777 filings](/companies/siga/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 16:46 ET | [10-Q](/filings/0001437749-26-026314.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026314 |
| 2026-08-06 | 16:06 ET | [8-K](/filings/0001140361-26-031672.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-031672 |
| 2026-06-10 | 16:05 ET | [8-K](/filings/0001140361-26-024780.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001140361-26-024780 |
| 2026-05-07 | 16:48 ET | [10-Q](/filings/0001437749-26-015646.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015646 |
| 2026-05-07 | 16:08 ET | [8-K](/filings/0001140361-26-019538.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-019538 |
| 2026-04-28 | 16:02 ET | [DEF 14A](/filings/0001140361-26-017421.md) | Proxy statement, period 2026-06-09 | 0001140361-26-017421 |
| 2026-03-26 | 16:05 ET | [8-K](/filings/0001140361-26-011361.md) | 8.01 Other events | 0001140361-26-011361 |
| 2026-03-10 | 16:50 ET | [10-K](/filings/0001437749-26-007557.md) | Annual report, period 2025-12-31 | 0001437749-26-007557 |
| 2026-03-10 | 16:05 ET | [8-K](/filings/0001140361-26-008782.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-008782 |
| 2025-11-06 | 16:53 ET | [10-Q](/filings/0001437749-25-033636.md) | Quarterly report, period 2025-09-30 | 0001437749-25-033636 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007557.md), filed Mar 10, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c9847105-8c08-4275-95df-dc753168301e)

## About the filer

- CIK: 1010086
- Tickers: SIGA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.